Colostrum from cows immunized with a veterinary vaccine against bovine rotavirus displays enhanced in vitro anti-human rotavirus activity by A. Civra et al.
  
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
4857
J. Dairy Sci. 102:4857–4869
https://doi.org/10.3168/jds.2018-16016
© American Dairy Science Association®, 2019.
ABSTRACT
Human rotaviruses represent a major cause of severe 
diarrheal disease in infants and young children. The 
limited impact of oral vaccines on global estimates of 
rotavirus mortality and the suboptimal use of oral rehy-
dration justify the need for alternative prophylactic and 
therapeutic strategies, especially for immunocompro-
mised hosts. The protective effects of colostrum—the 
first milk produced during the initial 24 to 48 h after 
parturition—are well documented in the literature. In 
particular, the ingestion of hyperimmune bovine colos-
trum has been proposed as an alternative preventive 
approach against human rotavirus gastroenteritis. Al-
though the immunization of pregnant cows with human 
rotavirus boosts the release of specific immunoglobulin 
G in bovine colostrum, it raises regulatory and safety 
issues. In this study, we demonstrated that the conven-
tional bovine rotavirus vaccine is sufficient to enhance 
the anti-human rotavirus protective efficacy of bovine 
colostrum, thus providing a conservative approach to 
produce hyperimmune bovine colostrum, making it 
exploitable as a functional food.
Key words: rotavirus, colostrum, cows, hyperimmune, 
immunoglobulins
INTRODUCTION
Viral gastroenteritis represents a significant economic 
and public health burden, causing high morbidity and 
mortality rates, mainly in the poorest countries (Das 
et al., 2014). Human rotaviruses (HRoV) are a major 
cause of severe diarrheal disease in infants and young 
children are the second most common cause of death 
in children less than 5 years old (Marcotte and Ham-
marström, 2016). Because no specific antiviral drug 
is available, conventional treatment for HRoV acute 
gastroenteritis is largely symptomatic and involves 
fluid and electrolyte replacement and maintenance of 
nutrition. Despite the introduction of oral HRoV vac-
cines that have significantly reduced the incidence of 
the disease in developed countries (Payne et al., 2013), 
the impact of this active prophylaxis on global esti-
mates of HRoV mortality has been limited (Tate et 
al., 2016). This is mainly due to inadequate immuni-
zation coverage in lower income countries, where the 
burden of diarrheal disease is higher and vaccines are 
mostly needed. In fact, oral vaccines are less immu-
nogenic when given to infants in low-income countries 
compared with high-income countries for a number of 
reasons, including transplacental maternally acquired 
antibodies, breastfeeding, histo blood group antigens, 
malnutrition, microbiota dysbiosis, and environmental 
enteropathy. Moreover, the scarce availability of vac-
cines in these areas, along with their contraindica-
tions in immunodeficient patients (Babji and Kang, 
2012; Binder et al., 2014; Gaspar et al., 2014; Glass 
et al., 2014), leave between one-third and one-half of 
children unprotected from severe HRoV disease (Babji 
and Kang, 2012). These hindrances, together with the 
suboptimal use of therapeutic oral rehydration solu-
tions, justify the development of effective alternative 
prophylactic and therapeutic approaches to prevent 
and control HRoV gastroenteritis disease, especially for 
immunocompromised hosts.
Colostrum is the first milk produced by mammary 
glands during the initial 24 to 48 h after parturition 
(Tokuyama et al., 1990; Stelwagen et al., 2009), and it 
represents a unique source of highly concentrated nu-
tritional components (Macy, 1949) and growth factors 
(Pakkanen and Aalto, 1997) for the gastrointestinal 
development of mammalian newborns.
More importantly, colostrum provides neonates with 
essential passive immunity against infectious diseases 
(Ogra and Ogra, 1978; Morris et al., 1980; Majumdar 
and Ghose, 1982; Stephan et al., 1990; Tokuyama et 
al., 1990; Ebina et al., 1992; Cohen, 2006; Stelwagen 
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et al., 2009). In particular, bovine colostrum (BC) has 
evolved into a highly effective host defense mechanism 
(Rainard and Riollet, 2006). In ruminants, no trans-
placental exchange of immune factors occurs in utero; 
therefore, colostrum and, to a lesser extent, mature 
milk provide protection through a high immunoglobu-
lin content, without which the newborn would not 
survive (Larson et al., 1980). The immunoglobulins 
present in BC are IgG1, IgG2, IgA, and IgM (Ogra 
and Ogra, 1978). The abundance of different immu-
noglobulin classes in colostrum and milk varies among 
species, with IgA being predominant in human mam-
mary secretions. In contrast, in BC, IgG1 is the most 
represented (Barrington et al., 1997), whereas IgA and 
IgM are present at much lower concentrations. The BC 
immunoglobulins, in conjunction with the ability of the 
ruminant neonatal gut to allow unrestricted passage of 
the large immunoglobulin molecules, provide the young 
animal with passive immunization (Bush and Staley, 
1980; Moore et al., 2005).
Although the effect of colostrum is species-specific, 
a growing body of literature has documented the pro-
tective effect of BC against several viral infections in 
humans (Bojsen et al., 2007; Ng et al., 2010; Benson 
et al., 2012; Inagaki et al., 2014; El-Fakharany et al., 
2017).
In particular, vaccination of cows against specific hu-
man pathogens results in polyclonal pathogen-specific 
antibodies in BC. The antibodies purified from this 
hyperimmune BC (HBC) have been exploited for the 
treatment of a variety of gastrointestinal infections 
caused by pathogenic bacteria (Playford et al., 2000; 
Kelly, 2003; Hammarström and Weiner, 2008; Struff 
and Sprotte, 2008) or viruses (Korhonen et al., 2000; 
Mehra, 2006; Inagaki et al., 2010, 2013; Ng et al., 2010; 
Byakwaga et al., 2011; Kramski et al., 2012a,b), in-
dicating that HBC could be an alternative source for 
low-cost virus-specific antibodies. This evidence, to-
gether with the high content of antimicrobial peptides 
and proteins (e.g., lactoferrin, lactoperoxidase, and 
lysozyme) that can stimulate innate antiviral pathways 
and adaptive immune responses (Thapa, 2005; Smolen-
ski et al., 2007; Stelwagen et al., 2009), suggests that 
BC could be exploited as a functional food to protect 
against viral infections.
Consistently, ingestion of HBC has been proposed 
as an alternative prophylactic approach against HRoV 
gastroenteritis (Ebina et al., 1992; Sarker et al., 1998). 
To date, HBC containing HRoV-specific, neutralizing 
IgG has been produced by immunizing pregnant cows 
with HRoV and harvesting colostrum after delivery. 
However, the additional costs and regulatory and 
safety issues arising from the use of an HRoV vaccine 
make it impossible to generate HBC on a large scale. 
The alternative use of BC from nonimmunized cows 
(NHBC) may bypass these limits but, as expected, 
the literature has shown that NHBC has significantly 
lower anti-HRoV efficacy (Inagaki et al., 2010). In 
this study, we present proof-of-concept data showing a 
protective effect of HBC from cows vaccinated with a 
conventional bovine rotavirus strain (BRoV) against 
different HRoV genotypes. 
MATERIALS AND METHODS
Chemicals
Laemmli buffer, molecular mass standards, and 
electrophoresis apparatus for one-dimensional electro-
phoresis were supplied by BioRad Laboratories Inc. 
(Hercules, CA). β-Mercaptoethanol, dithiothreitol, ace-
tonitrile, SDS, iodoacetamide, formic acid, and all other 
chemicals used in the experimental work were products 
of pure analytical grade and purchased from Sigma-
Aldrich Corp. (St. Louis, MO). Water and acetonitrile 
(Optima LC/MS grade) for liquid chromatography/MS 
analyses were purchased from Fisher Scientific (Lough-
borough, UK).
Bovine Colostrum Collection
Fresh BC and HBC samples were supplied by Ad-
vances in Medicine (AIM, Bologna, Italy). According 
to the supplier, colostrum was collected from both 
unvaccinated and vaccinated pregnant dairy Holstein 
cows. Three cows were immunized by subcutaneous in-
oculation of the inactivated trivalent vaccine Trivacton 
6 (Merial Italia SpA, Milan, Italy) to maintain a maxi-
mum rate of antibodies in colostral secretions against 
Escherichia coli, rotavirus, and coronavirus, which 
are implied in the development of neonatal diarrhea. 
Vaccination was performed with a 2-injection sched-
ule, administered 2 mo and 4 wk before parturition, 
respectively. Colostrum from the 3 vaccinated cows was 
collected until 5 h after birth, pooled, and immediately 
frozen at −20°C. Concentrations of IgG in whole colos-
trum samples was 50 mg/mL (protein content: 12%), 
as assessed by previously described methods (Sacerdote 
et al., 2013).
After a suitable dilution with demineralized water (1 
volume), the suspension was introduced into a sterile 
beaker (controlled continuous stirring) and heated at 
~38°C for about 1 h. The suspension was skimmed by 
removing the fatty layer using a sterile spatula, and 
caseins were removed by adjusting the pH to their iso-
electric point (pH 4.6 with 1 M HCl). After 1 h, the 
product was centrifuged at 2,500 × g for 45 min at 
25°C to ensure removal of all caseins. Low-molecular-
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weight components, including salts and lactose, were 
then removed by using hollow-fiber cross-flow filtration 
cartridges (GE Healthcare Bio-Sciences Corp., West-
borough, MA.) with a nominal molecular weight cutoff 
of 4000 coupled to a tangential flow filtration system 
equipped with a peristaltic pump essential to keep the 
flow recirculation continuous (Kross Flo-Tangential flow 
Filtration System Research III, Spectrum Laboratories 
Inc., Rancho Dominguez, CA). The pH of the retentate 
was then adjusted to 7.0 ± 0.2 with 1 M NaOH, the 
neutralized sample was centrifuged at 12,000 × g for 
40 min at 25°C, and the supernatant was retained. The 
next steps consisted of clarification through 0.45- and 
0.22-µm filters followed by lyophilization.
Bovine IgG Purification
Affinity Chromatography. Immunoglobulin G 
was purified by affinity chromatography, using protein 
G from streptococci as the stationary phase, immo-
bilized in a preparative chromatographic column. In 
detail, the affinity column was prepared by packing 
400 mL of Protein G Sepharose 4 Fast Flow resin 
(GE Healthcare, Chicago, IL) in a HiScale 50 column 
support (GE Healthcare), which was connected to a 
fast protein liquid chromatography (FPLC) system 
(ÄKTAprime plus, GE Healthcare). Chromatographic 
purification started by eluting the column with 5 vol-
umes (5 × chromatographic bed volume) of buffer A 
(binding buffer: 20 mM sodium phosphate, pH 7), and 
then the sample was loaded at a flow rate of 20 mL/
min. The eluate was monitored by a UV detector at 280 
nm, a conductivity meter (0.001–999.9 mS/cm), and a 
pH meter; all fractions characterized by significant UV 
absorption were automatically collected (IgG-depleted 
fractions). The subsequent step consisted of recovering 
the IgG fractions (IgG-enriched fractions) by eluting 
the column with 100% elution buffer (1 M glycine hy-
drochloride pH 2.5). Column regeneration was carried 
out by eluting 5 volumes (5 × chromatographic bed 
volume) of 20% ethanol.
Tangential Flow Filtration. The IgG-enriched and 
IgG-depleted fractions obtained above were mixed and 
subjected to concentration and desalting using hollow-
fiber cross-flow filtration cartridges with a nominal 
molecular weight cutoff of 3000 and a surface area of 
650 cm2 (GE Healthcare) coupled to a tangential flow 
filtration system equipped with a peristaltic pump es-
sential to keep the flow recirculation continuous (Kross 
Flo- Tangential flow Filtration System Research III). 
The IgG-enriched and IgG-depleted fractions were con-
centrated 20 to 30 times, dialyzed with 5 volumes of 
water, filtered through 0.22-µm membranes in sterile 
conditions, and finally lyophilized.
Separation of Proteins on Polyacrylamide Gel
One-dimensional (SDS-PAGE) protein separation 
was performed under reducing conditions; 10-µL ali-
quots of samples containing 20 to 25 µg of protein were 
mixed with 10 µL of Laemmli sample buffer containing 
50 mM dithiothreitol and heated at 95°C for 5 min. 
Samples and a standard protein mixture (Precision 
Plus Protein Standards, BioRad Laboratories Inc.) 
were loaded on precast gels (Any KD Mini Protean 
TGX, BioRad Laboratories Inc.) and then placed in 
the electrophoresis cell (Mini-Protean Tetra) and run 
at 200 V (constant) for 30 to 40 min. Staining was 
carried out using Coomassie blue stain (Biosafe G250 
Stain, BioRad Laboratories Inc.) and the images ac-
quired by using the BioRad GS800 densitometer and 
analyzed using the software Quantity One 1-D (BioRad 
Laboratories Inc.).
IgG and IgM Analysis by Size Exclusion 
Chromatography 
The IgG contents of the IgG-enriched and IgG-
depleted fractions were then determined by size exclu-
sion chromatography (SEC) according to the method 
reported by Altomare et al. (2016b); SEC was per-
formed on a Thermo Finnigan Surveyor HPLC system 
(ThermoFinnigan Italia, Milan, Italy) equipped with 
a variable wavelength detector and an auto-sampler, 
controlled by Xcalibur software (version 2.0.7 Thermo 
Fisher Scientific, Rodano, Italy). The SEC separation 
was performed on a 4.6- × 300-mm Phenomenex Yarra 
3u SEC-3000 column (Phenomenex Inc., Torrance, 
CA), with a 4 × 3 mm GFC4000 pre-column (Phe-
nomenex Inc.), by running an isocratic flow of mobile 
phase containing 0.1 M sodium phosphate bibasic, 
0.025% sodium azide, pH 6.8, at a constant flow rate of 
0.5 mL/min. The autosampler temperature was set at 
8°C and UV detection was conducted at a wavelength 
of 280 nm, typical wavelength for protein detection. 
The dipeptide tyrosine-histidine (TH) was chosen as 
internal standard, because it marks the racing front, 
being the smallest analyte. All samples were previously 
spiked with a small amount of TH (10 µL) in order to 
obtain a final concentration of 0.3 mM.
Cell Lines and Viruses
African green monkey kidney epithelial cells (MA104) 
and human epithelial adenocarcinoma HeLa cells 
(ATCC CCL-2) were propagated in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco-BRL, Gaithersburg, 
MD) supplemented with heat-inactivated 10% fetal bo-
vine serum (Gibco-BRL) and 1% antibiotic-antimycotic 
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solution (Zell Shield, Minerva Biolabs GmbH, Berlin, 
Germany), at 37°C in an atmosphere of 5% of CO2. 
African green monkey kidney cells (Vero cells; ATCC 
CCL-81) were grown as monolayers in Eagle’s minimal 
essential medium (Gibco/BRL) supplemented with 10% 
fetal bovine serum and 1% antibiotic-antimycotic solu-
tion. The HRoV strains Wa (ATCC VR-2018), HRV408 
(ATCC VR-2273), and HRV248 (ATCC VR-2274) and 
the BRoV strain NCDV (ATCC VR-1290) were acti-
vated with 5 µg/mL porcine pancreatic trypsin type IX 
(Sigma-Aldrich Co.) for 30 min at 37°C and propagated 
in MA104 cells using DMEM containing 0.5 µg of tryp-
sin per mL as described previously (Civra et al., 2015). 
Viral titers are expressed as focus-forming units (FFU) 
per milliliter. A serologic characterization of the ro-
taviruses exploited in this study is provided in Table 
1. Human rhinovirus (HRhV) 1A (ATCC VR-1559) 
was propagated in HeLa cells at 34°C in a humidified 
5% CO2 incubator. Clinical isolates of human herpes 
simplex virus type 1 (HSV1) and type 2 (HSV2) were 
provided by M. Pistello (University of Pisa, Italy). Hu-
man cytomegalovirus (HCMV) strain Towne was pro-
vided by W. Brune (Heinrich Pette Institut, Hamburg, 
Germany). Vesicular stomatitis virus (VSV; ATCC 
VR-1238), HCMV, HSV1, and HSV2 were propagated 
in Vero cells at 37°C in a humidified 5% CO2 incubator. 
When the full cytopathic effect developed, cells and su-
pernatants were harvested, pooled, frozen and thawed 
3 times, clarified, and aliquoted. Viruses were stored at 
−70°C. Viral titers were determined by the standard 
plaque method as described previously (Civra et al., 
2014; Cagno et al., 2017), and expressed as plaque-
forming units per milliliter (PFU/mL).
Focus Reduction Assay
Antiviral activity of NHBC, HBC, or IgG against 
HRoV Wa, HRV408, HRV248, and NCDV was deter-
mined by focus reduction assay or plaque reduction 
assay. Assays of inhibition of rotavirus infectivity were 
carried out with confluent MA104 cell monolayers 
plated in 96-well trays, as described elsewhere (Civra et 
al., 2014). Cells were treated for 2 h at 37°C with serial 
dilutions of colostrum, at protein concentrations rang-
ing from 0.02 to 3,340 µg of protein/mL in serum-free 
medium before virus addition. Infection with HRoV 
was performed at a multiplicity of infection (MOI) 
of 0.02 FFU/mL for 1 h at 37°C, in presence of the 
colostrums. Infected cells were washed with serum-free 
medium, fresh methanol extract was added, and cells 
were incubated in this medium at 37°C in a humidified 
incubator in 5% (vol/vol) CO2 in 95% (vol/vol) air. 
After 16 h of incubation, infected cells were fixed with 
cold acetone-methanol (50:50), and viral titers deter-
mined by indirect immunostaining by using a mouse 
monoclonal antibody directed to human rotavirus VP6 
(0036; Covalab, Villeurbanne, France), and the second-
ary antibody peroxidase-conjugated AffiniPure F(ab′)2 
Fragment Goat Anti-Mouse IgG (H+L) (Jackson Im-
munoResearch Laboratories Inc., West Grove, PA).
Table 1. Rotavirus strains used in this study1
Strain  Origin  Serotype2
Wa Human G1[P8]
HRV408 Human Natural reassortant G3[P?]
HRV248 Human Natural reassortant G4[P4]
NCDV Bovine G6[P1]
1The characteristics of the rotavirus strains are from Parrón et al. 
(2018) and Rahman et al. (2012).
2[P?] = P genotype unknown.
Figure 1. Sodium dodecyl sulfate-PAGE profiling of colos-
trum proteins. Lane 1 = Precision Plus Protein Standard (BioRad 
Laboratories, Hercules, CA); lane 2 = untreated bovine colostrum; 
lane 3 = untreated hyperimmune bovine colostrum; lane 4 = bovine 
colostrum defatted, casein-depleted, dialyzed, and filtered; lane 5 = 
hyperimmune bovine colostrum defatted, casein-depleted, dialyzed, 
and filtered.
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Plaque Reduction Assay
For the plaque reduction assay, HeLa or Vero cells 
were first seeded (at 8 × 104 cells/well) in 24-well 
plates. Twenty-four hours later, HBC, NHBC, or IgG 
was serially diluted in medium (from 0.02 to 3,340 µg 
of protein/mL) and added to cell monolayers. After 
2 h of incubation (37°C, 5% CO2), medium was re-
moved and infection was performed with 200 µL/well 
of HRhV 1A, VSV, HSV-1, HSV-2, or HCMV at an 
MOI of 0.0002 PFU/mL in presence of colostrums. 
The infected cells were incubated at 34°C for HRhV 
infections or 37°C for the other viruses for 1 h, washed 
with medium, and overlaid with a 1:1 combination of 
1.6% SeaPlaque Agarose and 2× DMEM containing 
the colostrums. Control wells (100% of infection) were 
prepared by treating cells with equal volumes of culture 
medium. The plates were incubated at 34°C or 37°C for 
3 d. After incubation, the plates were fixed with 7.5% 
formaldehyde (Fluka, Bucharest, Romania) and stained 
with crystal violet (Sigma-Aldrich Co.). The number of 
plaques formed was counted.
Rotavirus Neutralization Assay
Immunoglobulin G precipitated with ammonium 
sulfate (AS) was added at a 90% effective concentra-
tion (EC90) to 2 × 105 FFU/mL of trypsin-activated 
RoV suspension and mixed in a total volume of 200 µL. 
Untreated or negative controls were performed with an 
equal volume of culture medium or AS supernatant. 
Figure 2. Purification of IgG by affinity chromatography. (a) Fast protein liquid chromatography-UV chromatogram of the untreated-bovine 
colostrum (casein-depleted and defatted colostrum) obtained by using protein G as affinity stationary phase; peaks 1 and 2 represent, respec-
tively, the IgG-depleted and IgG-enriched fractions as demonstrated by the SDS-PAGE patterns. (b) Gel electrophoretic pattern of peaks 1 (lane 
3) and 2 (lane 4) compared with the untreated bovine colostrum pattern, run under reducing conditions. The characteristic bands at 25 and 50 
Da are evident in peak 2 and negligible in peak 1. BIORAD = BioRad Laboratories (Hercules, CA).
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The virus-compound mixtures were incubated for 1 h 
at 37°C, serially diluted to the noninhibitory concentra-
tion of test IgG, and the residual viral infectivity was 
determined as previously described (Civra et al., 2014).
Rotavirus-Cell Binding Assay
Rotavirus-cell binding assays were performed as de-
scribed previously (Civra et al., 2015). Trypsin-activat-
ed RoV strains Wa, HRV248, HRV408, and NCDV were 
treated as described for the neutralization assays. After 
1 h, cells were washed with fresh medium and cooled 
on ice. The RoV were then cooled to 4°C and allowed 
to attach to cells for 1 h (MOI = 3 FFU/cell) at 4°C. 
After a wash with cold DMEM, cells were subjected to 
2 rounds of freeze/thawing and then incubated at 37°C 
for 30 min with 10 µg/mL porcine trypsin to release 
bound virus. The lysates were then clarified by low-
speed centrifugation for 10 min, and cell-bound virus 
titers were determined by indirect immunostaining as 
above.
Cell Viability Assay
Cells were seeded at a density of 5 × 103/well in 96-
well plates and treated the next day with HBC, NHBC, 
IgG, or AS supernatant at concentrations ranging from 
0.02 to 7,140 µg/mL to generate dose–response curves. 
Control samples (100% of viability) were prepared by 
treating cells with culture medium. After 24 or 72 h 
of incubation, cell viability was determined using a 
CellTiter 96 Proliferation Assay Kit (Promega, Madi-
son, WI), following the manufacturer’s instructions. 
Absorbances were measured using a Microplate Reader 
Figure 3. Analysis of IgG by size exclusion chromatography (SEC)-UV; (a) shows the SEC-UV chromatogram of the IgG-depleted bovine 
colostrum sample, using the dipeptide tyrosine-histidine (TH) as internal standard; (b) shows the SEC-UV chromatogram of IgG purified frac-
tion from bovine colostrum.
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(model 680, BioRad Laboratories) at 490 nm. Viability 
of treated cells was expressed as a percentage relative 
to cells incubated with culture medium.
Statistical Assessments
Blockades of viral infectivity were expressed as mean 
percent ± standard deviation (SD). Where possible, 
antiviral effective concentration (EC50) values were cal-
culated by regression analysis using the dose–response 
curves generated from the experimental data, using 
Prism 4 (GraphPad Software, San Diego, CA). The 
50% cytotoxic concentration (CC50) was determined 
using logarithmic viability curves. Where possible, a 
selectivity index (SI) was calculated by dividing CC50 
by EC50. One-way ANOVA followed by Bonferroni test 
was used to assess the statistical significance of the dif-
ferences between treated and untreated samples. The 
EC50 values were compared using the sum-of-squares F 
test. Significance was set at the 95% level.
RESULTS
One-Dimensional Gel Electrophoresis
Figure 1 displays the SDS-PAGE profile of colos-
trum proteins (under reducing conditions) relative to 
the following samples: colostrum from nonimmunized 
(lane 2) and immunized (lane 3) cows and the corre-
sponding defatted, casein-depleted, dialyzed, filtered 
samples (lanes 4 and 5). As expected, all protein pro-
files showed 2 intense bands at approximately 50 and 
25 kDa, representing the heavy and light IgG chains, 
respectively. The other bands represent the classical 
set of high-abundance species normally found in any 
milk of animal origin (although in colostrum, IgG alone 
represent ~80% of the total protein mass), including 
α-lactalbumin (14.1 kDa), β-lactoglobulin (19.9 kDa), 
serum transferrin (77.7 kDa), and α2-macroglobulin 
(167.5 kDa). As expected, the protein patterns relative 
to colostrum samples differed in respect to the corre-
sponding defatted, casein-depleted, dialyzed, filtered 
samples by a significant reduction in the bands attrib-
utable to the caseins (lanes 2 and 3, Figure 1).
Bovine IgG Purification by Affinity Chromatography
Purification of IgG from colostrum collected from 
nonimmunized and immunized cows was achieved by 
using a preparative affinity chromatography system 
based on protein G from streptococci, which is highly 
selective against bovine IgG.
The affinity chromatogram trace, recorded at 280 
nm, displayed 2 peaks: the first (not retained) corre-
sponded to the non-immunoglobulin protein fraction, 
and the second to the IgG fraction (Figure 2a), the 
Table 2. Antiviral activities1 of bovine colostrums (BC)
BC and virus2  
(strain)
EC50 (µg/mL) 
(95% CI)
EC90 (µg/mL) 
(95% CI)
CC50 
(µg/mL) SI
Nonimmune BC
 HSV-1  NA3 NA >6,680 —
 HSV-2 NA NA >6,680 —
 HCMV NA NA >6,680 —
 HRhV NA NA >6,680 —
 HRoV (Wa) 2.3 (1.6–3.5) 16.3 (6.8–39.1) >6,680 >2,855
 HRoV (HRV408) 12.6 (8.6–18.7) 90 (38–215) >6,680 >529
 HRoV (HRV248) 4.2 (2.4–7.3) 134 (39–454) >6,680 >1,591
 BRoV (NCDV) 61 (44–86) 143 (97–211) >6,680 >109
 VSV 64 (55–75) 343 (252–467) >6,680 >104
Hyperimmune BC
 HSV-1 NA NA >7,140 —
 HSV-2 6,018 (2,560–14,110) NA >7,140 >1.18
 HCMV NA NA >7,140 —
 HRhV NA NA >7,140 —
 HRoV (Wa) 0.3 (0.3–0.5) 4.5 (2.4–8.5) >7,140 >21,000
 HRoV (HRV408) 2.1 (1.7–2.6) 7.6 (4.7–12.5) >7,140 >3,449
 HRoV (HRV248) 1.6 (1.2–2.8) 8.1 (5.6–11.6) >7,140 >4,519
 BRoV (NCDV) 5.5 (3.7–8.2) 51 (21–122) >7,140 >1,301
 VSV 89 (60–132) 489 (200–1198) >7,140 >80
1EC50 = half-maximal effective concentration; EC90 = 90% effective concentration; CC50 = half-maximal cyto-
toxic concentration; SI = selectivity index (CC50/EC50).
22HSV-1 = herpes simplex type 1; HSV-2 = herpes simplex type 2; HCMV = human cytomegalovirus; HRhV 
= human rhinovirus; HRoV = human rotavirus; BRoV = bovine rotavirus; VSV = vesicular stomatitis virus.
3Not assessable.
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peak of which accounted for 80%. The electrophoretic 
patterns obtained for the 2 collected fractions (Figure 
2b) indicated good depletion of immunoglobulins, 
whose characteristic bands at 160, 50, and 25 kDa were 
very weak in the aliquot eluted within the first peak 
and much more intense in the fraction of the second 
peak, corresponding to the immunoglobulins.
SEC-UV for IgG Analysis
A SEC-UV method was optimized to achieve re-
producible separation of the most abundant analytes 
in bovine colostrum; the method was then applied to 
verify the purity of the fractions obtained: the non-
immunoglobulin protein fraction and the IgG eluted 
fraction.
Figure 3 represents typical chromatograms recorded 
by setting the UV detector at 280 nm and relative to 
the IgG-depleted (Figure 3a) and IgG-enriched (Figure 
3b) fractions, each spiked with the internal standard 
TH (0.3 mM). The typical retention times for IgG and 
the dipeptide TH were 9.15 and 11.57 min, respectively. 
The peak relative to IgG was evident only in the IgG-
enriched fraction and absent in the IgG-depleted frac-
tion, which was characterized by other peaks such as 
representing IgM and β-lactoglobulin
Figure 4. Antiviral activity of colostrum from immunized cows (hyperimmune bovine colostrum, HBC) and colostrum from nonimmunized 
cows (NHBC) against human rotavirus (HRoV) strains Wa (a), HRV408 (b), and HRV248 (c) and bovine rotavirus (BRoV) strain NCDV (d) 
on MA104 cells. Cells were treated for 2 h with increasing concentrations of colostrum and then infected in the presence of colostrum. Viral 
infections were detected as described in the Material and Methods. The percentage infection was calculated by comparing treated and untreated 
wells. The results are means and SEM for duplicates.
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Antiviral Activity Assessment
After their biochemical characterization, colostrums 
and IgG samples were tested for antiviral activity. The 
results summarized in Table 2 show that neither NHBC 
nor HBC had antiviral activity against human patho-
gens, including HSV-1, HCMV, or HRhV. Although 
HBC showed a weak antiviral activity against HSV-2, 
nevertheless it was not able to inhibit viral infectiv-
ity to 100%. As expected, NHBC was effective against 
bovine pathogens such as BRoV NCDV (EC50 = 61.5 
µg of protein/mL) and VSV (EC50 = 64 µg of protein/
mL; Table 2). Of note, NHBC had non-strain-restricted 
antiviral efficacy against the HRoV strains Wa (EC50 
= 2.3 µg of protein/mL), HRV248 (EC50 = 4.2 µg of 
protein/mL), and HRV408 (EC50 = 12.6 µg of protein/
mL) with percentages of inhibition up to 100% (Figure 
4). To test the hypothesis that colostrum from cows 
immunized with a veterinary anti-BRoV vaccine may 
exert a higher anti-HRoV activity than that from non-
immunized cows, we performed a second set of antiviral 
assays. As expected, HBC exerted significantly (P < 
0.0001; F test) higher antiviral activity against BRoV 
NCDV (EC50 = 5.5 µg of protein/mL), compared with 
colostrum of nonimmunized cows (Table 2). This result 
indicates that vaccination elicited an anti-BRoV im-
mune response. Notably, HBC was also significantly 
(0.0001 < P < 0.0005; F test) more effective than 
NHBC against Wa (EC50 = 0.3 µg of protein/mL), 
HRV248 (EC50 = 1.6 µg of protein/mL), and HRV408 
(EC50 = 2.1 µg of protein/mL; Table 2), suggesting 
a high titer of cross-reactive IgG in HBC. Therefore, 
we performed a third set of experiments to test the 
presence of anti-HRoV IgG in HBC-derived IgG. The 
results shown in Table 3 and Figure 5 demonstrate that 
these IgG inhibit the infectivity of BRoV strain NCDV 
(EC50 = 6.2 µg of protein/mL) but, more interestingly, 
also have strong antiviral activity against HRoV strains 
Wa (EC50 = 1.9 µg of protein/mL), HRV248 (EC50 = 
0.7 µg of protein/mL), and HRV408 (EC50 = 1.8 µg 
of protein/mL) with percentages of inhibition up to 
100%. As a negative control for IgG antiviral assays, 
we treated cells with equal volumes of IgG-depleted 
AS supernatant; results shown in Table 3 and Figure 
5 show that the IgG-depleted AS supernatant did not 
have significant antiviral activity. Notably, treatment 
of the different cell lines with NHBC, HBC, and IgG 
did not affect cell viability, even at high concentrations, 
showing that the antiviral activity we observed was not 
caused by nonspecific cytotoxic effects.
Mechanism of action experiments show that these 
IgG neutralize virus infectivity by significantly (0.0103 
< P < 0.0155; ANOVA) inhibiting RoV-cell bind-
ing (Figure 6a,b,c). More importantly, the significant 
(0.0005 < P < 0.0183; ANOVA) neutralization of viral 
infectivity observed in virus inactivation assays (Figure 
6d,e,f) was consistent with a neutralizing activity of 
virus-specific antibodies targeting RoV surface anti-
gens, rather than cellular receptors.
DISCUSSION
The supportive properties of BC when consumed by 
other mammalian species, including pigs and humans, 
are well documented in the medical literature (Bridger 
and Brown, 1981; Pakkanen and Aalto, 1997; Gopal and 
Gill, 2000; He et al., 2001; Solomons, 2002; Uruakpa et 
al., 2002; Boudry et al., 2007; Struff and Sprotte, 2007). 
Emerging evidence indicates that BC is a promising 
nutraceutical that could prevent or mitigate various 
diseases in newborns and adults (Bagwe et al., 2015), 
in particular gastrointestinal infections. Consistent 
with these findings, in this study we confirmed the 
protective activity of NHBC against HRoV, which is 
Table 3. Antiviral activities1 of IgG from hyperimmune bovine colostrum
Sample and virus2 (strain)
EC50 (µg/mL) 
(95% CI)
EC90 (µg/mL) 
(95% CI)
CC50 
(µg/mL) SI
IgG
 HRoV (Wa) 1.9 (1.4–2.6) 19.7 (10.4–37.1) >5,910 >3,110
 HRoV (HRV408) 1.8 (0.8–3.9) 12.6 (2.5–63.2) >5,910 >3,283
 HRoV (HRV248) 0.7 (0.6–0.9) 8.2 (4.9–13.9) >5,910 >8,443
 BRoV (NCDV) 6.2 (5.2–7.4) 30.2 (19.7–49.0) >5,910 >953
Ammonium sulfate supernatant
 HRoV (Wa)  NA3 NA >5,910 NA
 HRoV (HRV408) NA NA >5,910 NA
 HRoV (HRV248) NA NA >5,910 NA
 BRoV (NCDV) NA NA >5,910 NA
1EC50 = half-maximal effective concentration; EC90 = 90% effective concentration; CC50 = half-maximal cyto-
toxic concentration; SI = selectivity index (CC50/EC50).
2HRoV = human rotavirus; BRoV = bovine rotavirus. 
3Not assessable.
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well documented in the literature (Inagaki et al., 2010, 
2013). Of note, NHBC also showed antiviral activity 
against several HRoV strains and, as expected, against 
BRoV strain NCDV, at concentrations comparable to 
those previously shown (Inagaki et al., 2013).
In our experimental setting, NHBC showed no sig-
nificant antiviral activity against 4 viral pathogens; 
namely, HRhV, HCMV, HSV-1, and HSV-2. These 
results show that BC is not a broad-spectrum antiviral 
but rather it exerts specific antiviral activities. It is 
likely that this antiviral specificity and potency reflects 
the immunological status of the animal.
Boosting the natural concentrations of immune com-
ponents in colostrum and milk by vaccinating cows 
offers great potential for their use as prophylactic or 
therapeutic products in humans. Hyperimmune BC 
from cows vaccinated with HRoV was an effective 
therapeutic approach to reduce the duration and sever-
ity of RoV-caused diarrhea in a double-blind controlled 
clinical study with infants of 6 to 24 mo of age (Mitra 
et al., 1995). In a second study, Davidson et al. (1989) 
produced HBC by introducing a vaccine containing 4 
HRoV into pregnant Friesian cows. They demonstrated 
that this HBC administered orally mediated protection 
by preventing HRoV infection. Efficacy of passive im-
munization with HBC-derived IgG is documented in 
the literature. Hilpert et al. (1987) treated infants hos-
pitalized with acute diarrhea with anti-rotavirus immu-
noglobulin concentrate without observing a significant 
decrease in duration of diarrhea or excretion of virus. 
Turner and Kelsey (1993) demonstrated a reduction in 
incidence and duration of diarrhea in treated infants. 
Sarker et al. (1998) produced HBC by immunizing 
pregnant cows with HRoV strains Wa, RV3, RV5, and 
Figure 5. Antiviral activity of hyperimmune bovine colostrum (HBC)-derived IgG or ammonium sulfate (AS) supernatant against human 
rotavirus (HRoV) strains Wa (a), HRV248 (b), and HRV408 (c) and bovine rotavirus (BRoV) strain NCDV (d) on MA104 cells. Viral infections 
were detected as described in Material and Methods. The percentage infection was calculated by comparing treated and untreated wells. The 
results are means and SEM for duplicates.
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ST3 (representing serotypes 1 to 4, respectively). The 
HBC-purified IgG were then administered in a double-
blind placebo-controlled trial to children with diagnosed 
HRoV diarrhea. Children who received HBC-IgG had 
significantly less daily and total stool output and fre-
quency and required less oral rehydration solution than 
did children who received placebo. However, it is difficult 
to generate large-scale amounts of HBC by immunizing 
cows with an unconventional HRoV vaccine; indeed, 
the yield is insufficient to cover the global requirement 
because over 500,000 deaths occur worldwide every year 
due to rotavirus-induced diarrhea (Bagwe et al., 2015). 
To overcome these limitations, we proposed and tested 
the hypothesis that HBC from cows immunized with a 
conventional veterinary vaccine against BRoV would 
exert a higher anti-HRoV activity than NHBC due to a 
high titer of cross-reactive anti-HRoV IgG. Indeed, our 
results confirm this hypothesis and indicate an easier 
and cheaper approach for the production of anti-HRoV 
HBC or IgG in cows. We demonstrated an in vitro 
HRoV inhibition efficacy (i.e., EC50) of HBC compa-
rable to that of Inagaki and colleagues, who treated 
MA104 cells with skimmed and concentrated bovine 
late colostrum from HRoV-immunized cows (Inagaki 
et al., 2010, 2013). We demonstrated that HBC and its 
IgG can inhibit the infectivity of 4 RoV with 4 different 
Figure 6. Mechanism of action of hyperimmune bovine colostrum (HBC)-derived IgG, untreated colostrum, or ammonium sulfate (AS) 
supernatant on rotavirus strains. Panels a, b, and c show the effect of HBC-derived IgG on Wa, HRV248, and NCDV, respectively, binding 
to the MA104 cell surface. Panels d, e, and f show the results of virus inactivation assays on infectious particles of Wa, HRV248, and NCDV, 
respectively. On the y-axis, the infectious titers of HRoV are expressed as focus-forming units per milliliter (FFU/mL). Error bars represent the 
SEM of independent experiments. *P < 0.05, **P < 0.001, ***P < 0.0001. HRoV = human rotavirus; BRoV = bovine rotavirus.
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GP genotypes (Table 1), suggesting that vaccination 
with BRoV stimulates the production of cross-reactive 
neutralizing antibodies.
With a view to exploiting HBC as a source of anti-
HRoV IgG, quality assessment procedures are neces-
sary to monitor the IgG content; nevertheless, these 
techniques are already available and well documented in 
the literature (Altomare et al., 2016a). Moreover, cows 
produce BC in large excess respective to the amount 
needed to feed their calves: cows produce about 33 L of 
colostrum each day in the first days after parturition, 
but just 4 to 6 L/d is administered to the calf during 
the first 2 d (Devery-Pocius and Larson, 1983).
Overall, we demonstrated that the conventional 
BRoV vaccine is sufficient to boost the anti-HRoV pro-
tective efficacy of BC. This represents a conservative, 
feasible, and not yield-limiting approach to produce 
HBC that could be exploited as a functional food to 
prevent and treat HRoV infections.
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